Ultimovacs to Present at Cowen Healthcare Conference

27 Feb 2023 08:00 CET

Oslo, February 27, 2023: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-
stage biotechnology leader in novel immunotherapeutic cancer vaccines, announces
today that Carlos de Sousa, Chief Executive Officer and Jens Bjørheim, Chief
Medical Officer, will present Ultimovacs at the Cowen Healthcare Conference on
Monday, March 6 at 2:50 PM (EST). A webcast of the presentation will be
available on the Company website.

Cowen's 43rd Annual Health Care Conference is?taking place March 6 - 8, 2023, at
the Boston Marriott Copley Place in Boston, MA.??The conference incorporates
presentations, fireside chats and innovative panel discussions hosted by members
of the Cowen research team that focus on various aspects of the healthcare
industry.


About Ultimovacs

Ultimovacs is a clinical-stage biotechnology leader developing novel
immunotherapeutic cancer vaccines to treat a broad range of cancer types.
Ultimovacs' lead universal cancer vaccine candidate, UV1, targets human
telomerase (hTERT), present in 85-90% of cancers in all stages of tumor growth.
By directing?the immune system to hTERT antigens, UV1 drives CD4 helper T cells
to the tumor to activate an immune system cascade and increase anti-tumor
responses. With a broad Phase II program in five cancer indications enrolling
more than 650 patients in Europe, the US and Australia, Ultimovacs aims to
clinically demonstrate UV1's impact in multiple cancer types, in combination
with other immunotherapies, for patients with unmet needs. Ultimovacs' second
technology approach, the proprietary Tetanus-Epitope-Targeting (TET) platform,
combines tumor-specific peptides and a tetanus-based adjuvant in the same
molecule.




For further information, please see www.ultimovacs.com or contact:


Carlos de Sousa, CEO
Email: carlos.desousa@ultimovacs.com
Phone: +47 908 92507


Anne Worsøe, Head of IR & Communication
Email: anne.worsoe@ultimovacs.com
Phone: +47?906 86815


Mary-Ann Chang, LifeSci Advisors
Email: mchang@lifesciadvisors.com
Phone: +44 7483 284?853





This non-regulatory stock exchange announcement was published by Anne Worsøe,
Head of IR at Ultimovacs ASA, on February 27, 2023 at 08:00CET.

More information:
Access the news on Oslo Bors NewsWeb site